BriaCell Therapeutics Corp. (BCTX) Cash from Financing Activities (2019 - 2025)

BriaCell Therapeutics has reported Cash from Financing Activities for 6 years, with the latest figure at $13.6 million in Q3 2025.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $13.6 million in Q3 2025, while the trailing twelve-month figure through Apr 2026 was $33.5 million (down 6.7% YoY) and the FY2025 annual result came in at $45.4 million, up 928.49% from the prior year.
• Cash from Financing Activities slipped to $13.6 million in Q3 2025 per BCTX's latest filing, from $14.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $38.3 million in Q3 2021 and troughed at -$159783.0 in Q3 2022.
• A 5-year average of $10.4 million and a median of $5.2 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 100.42% in 2022, then soared 2603.4% in 2023.
• Over 5 years, Cash from Financing Activities stood at $38.3 million in 2021, then sank by 100.12% to -$47294.0 in 2022, then jumped by 8557.73% to $4.0 million in 2023, then surged by 199.01% to $12.0 million in 2024, then gained by 13.35% to $13.6 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $13.6 million, $14.7 million, and $5.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.